

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6


# Experimental Protocol


5TGM1



Docket No: A061CIP1  
Application No.: 09/943,659 Confirmation No.: 2421  
Inventor: MUNDY et al.  
Title: Methods of Treating Multiple Myeloma and  
Myeloma-Induced Bone Resorption Using Integrin  
Antagonists

Figure 7





EFFECT OF PS/2 mAb TREATMENT  
ON SPLEEN WEIGHT




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES  
IN MICE WITH 5TGM1 MYELOMA





Figure 11


## EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE

DISEASE FREE




File: do111700.077	Acquisition Date: 17-Nov-00
Gate: G1	Gated Events: 9624
Total Events: 10707	Quad Location: 523, 25
Quad	Events % Gated % Total X Mean Y Mean
UL	9499 86.70 86.72 37.11 1120.67
UR	3 0.03 0.03 5084.96 773.52
LL	122 1.27 1.14 31.88 11.09
LR	0 0.00 0.00 *** ***

UNTREATED




File: do111700.100	Acquisition Date: 17-Nov-00
Gate: G1	Gated Events: 9526
Total Events: 11100	Quad Location: 523, 25
Quad	Events % Gated % Total X Mean Y Mean
UL	4959 52.06 44.68 84.30 1023.41
UR	1388 14.57 12.50 2377.81 704.20
LL	2163 22.71 19.49 50.53 6.64
LR	1016 10.67 9.15 3619.03 4.05

PS/2 TREATED



File: do111700.120	Acquisition Date: 17-Nov-00
Gate: G1	Gated Events: 9561
Total Events: 10934	Quad Location: 523, 25
Quad	Events % Gated % Total X Mean Y Mean
UL	7868 82.29 71.96 58.00 1139.33
UR	310 3.24 2.84 1922.82 897.47
LL	1171 12.25 10.71 42.10 8.17
LR	212 2.22 1.94 3153.17 3.62

rat IgG2b TREATED



File: do111700.137	Acquisition Date: 17-Nov-00
Gate: G1	Gated Events: 9598
Total Events: 10970	Quad Location: 523, 25
Quad	Events % Gated % Total X Mean Y Mean
UL	4910 51.17 44.76 84.95 975.18
UR	1384 14.42 12.62 1937.36 694.49
LL	1704 17.76 15.53 48.67 7.00
LR	1597 16.64 14.56 3266.15 2.68

Figure 12

### EFFECT OF PS/2 mAb TREATMENT ON SPLEN TUMOR BURDEN




Figure 13

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS  
IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN  
mlgG2b POSITIVE CELLS




Figure 15

EFFECT OF PS12 mAb TREATMENT  
ON 5TGMI CELLS IN THE BLOOD




Figure 16

EFFECT OF PS/2 TREATMENT ON  
BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON  
CIRCULATION mIgG2b LEVELS




Figure 18

2002-05-29 09:35:16.600  
**C57/Bl KALWRAJ MULTIPLE MYELOMA MODEL**  
**ACUTE TREATMENT PROTOCOLS**




Figure 19

INDUSTRIAL DESIGN

EFFECT OF PS2 TREATMENT ON IgG2b POSITIVE CELLS  
ACUTE TREATMENT MODEL




Figure 20

THERAPEUTIC USES OF INTEGRINS

EFFECT OF ANTI VLA-4 ANTIBODY PS2  
ON TUMOR BURDEN IN SPLEEN




Figure 2:

EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

EFFECT OF 6 DAYS OF PS2 TREATMENT ON BONE MARROW CELLS




Figure 23

C57BLK1W<sup>+</sup>Raj MODEL OF MULTIPLE MYELOMA  
COMBINATION TREATMENT WITH PS/2 AND MELPAHLAN




Figure 24

EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27




Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detected	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 $\mu$ g/ml	none detected
13-melphalan+PS/2	none detected	none detected

Figure 28

C57/B1K/LwRaj MODEL OF MULTIPLE MYELOMA  
PS2 AND ANTI VLA4 SMALL MOLECULE  
LONG TERM TREATMENT




Figure 29

EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

### EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

C57/B1K/LwRaj MODEL OF MULTIPLE MYELOMA  
PS2 AND ANTI VLA4 SMALL MOLECULE  
ACUTE TREATMENT



STGMI CELLS (1E6) INJECTED/DLV ON DAY 0  
PS2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP  
DISEASE FREE CONTROL,  
UNTREATED MYELOMA CONTROL  
PS2 -100 micrograms/injection  
8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg  
9257 CONTROL - 3 mg/kg

Figure 32

EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

## EFFECT OF ACUTE TREATMENT ON TUMOR BURDEN




Figure 34

## Experimental Protocol




Figure 35

## Inhibition of Hindleg Paralysis




Figure 36